STOCKHOLM - April 24, 2024 - Inify Laboratories, a unique laboratory service
provider within pathology and cancer diagnostics, saw a 184% increase in sales
in Q1 2024, compared to the previous quarter.

"What we see now is the result of many years of preparation. More diagnoses were
delivered in the first quarter alone than in the whole of 2023. The company's
whole organization is ready for the significant increase in sales that we
foresee both this year, and the years to come," says CEO Fredrik Palm at Inify
Laboratories.

Inify is experiencing a great deal of interest from new customers, and expects
continued strong growth during the year. Dialogues with new customers include
both public and private healthcare providers, as structures for healthcare
delivery vary between regions in the country.

"The growth we see in the number of samples and turnover is clear acknowledgment
of the value we create and the trust we build with our customers," says Palm.

The market for diagnosis of prostate cancer will continue to grow. Long,
unpredictable response times and varying quality pose great challenges for most
countries, and the number of cases of prostate cancer globally is expected to
increase significantly by 2040.

"In parallel with our establishment in Sweden, our evaluation of selected
markets in Europe is ongoing. We primarily focus on countries that are initially
able to send patient samples to Sweden, which gives us a good basis for a
decision whether to establish laboratory operations in these countries," says
Palm.

Inify's success depends on having the best possible team. Therefore the company
continues to grow its organization, welcoming new colleagues in the first
quarter as well as those who will join later this year.

"Our team has been strengthened with employees in marketing, diagnostics,
customer support and laboratory expertise. This is fully in line with our plans
and means that we are well staffed for the growth we see ahead," says Palm.

For further information, please contact CEO, Fredrik Palm,
fredrik.palm@inify.com, or visit https://www.inify.com

###

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory
services within pathology. It uses a fully digital, standardized and AI
-supported workflow to optimize quality and response times, initially within
prostate.The concept is scalable and can be extended to other diagnoses.
The service includes the whole chain of sample handling: from logistics, to
sample preparation, to reporting by a pathologist. The report is assisted by our
own AI, proven in clinical studies to have world-leading accuracy. The complete
workflow is supported by a tailor-made process control system.
The company, based in Sweden, became independent in 2022 through a spin-off
fromContextVision (https://www.contextvision.com/), with 40 years of experience
within digital imaging for medical applications. It is listed onEuronext Growth
Oslo under the ticker
INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.